The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis With Positive IGRA
Condition:   Tuberculous Uveitis Interventions:   Drug: Anti Tuberculosis Drug;   Drug: Prednisone tablet Sponsor:   Fakultas Kedokteran Universitas Indonesia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 13, 2021 Category: Research Source Type: clinical trials

The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis With Positive IGRA: A Randomized Clinical Trial
Condition:   Tuberculous Uveitis Interventions:   Drug: Anti Tuberculosis Drug;   Drug: Prednisone tablet Sponsor:   Fakultas Kedokteran Universitas Indonesia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 13, 2021 Category: Research Source Type: clinical trials

Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis
Condition:   TUBERCULOSIS, PULMONARY Intervention:   Diagnostic Test: ISIT-TB prototype Sponsor:   BioMérieux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2021 Category: Research Source Type: clinical trials

Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
Condition:   Tuberculosis Infection Intervention:   Sponsor:   Asan Medical Center Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 4, 2021 Category: Research Source Type: clinical trials

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials
ConclusionsIn a review of 31 clinical trials, we found that outcome definitions were heterogeneous, highlighting the need to establish clearer specification and a move towards universal standardization of outcomes across pulmonary TB trials. The ICH E9 (R1) addendum provides guidelines for undertaking and achieving this goal.PROSPERO registrationPROSPEROCRD42020197993. Registration 11 August 2020. (Source: Trials)
Source: Trials - August 3, 2021 Category: Research Source Type: clinical trials

Potential Role of Gut Microbiome in Tuberculosis
Condition:   Tuberculosis Intervention:   Sponsors:   Khyber Medical University Peshawar;   University of Reading;   TB Control Program Khyber Pakhtunkhwa Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2021 Category: Research Source Type: clinical trials

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Condition:   Tuberculosis Interventions:   Biological: MTBVAC;   Biological: BCG Sponsors:   Biofabri, S.L;   TuBerculosis Vaccine Initiative;   University of Cape Town;   Institut Pasteur de Madagascar;   Biomedical Research Center EPLS;   Universidad de Zaragoza;   University of Stellenbosch;   University of KwaZulu;   Wits Health Consortium (Pty) Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Condition:   Tuberculosis Interventions:   Biological: GamTBvac;   Biological: Placebo Sponsor:   Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Condition:   Tuberculosis Interventions:   Biological: MTBVAC;   Biological: BCG Sponsors:   Biofabri, S.L;   TuBerculosis Vaccine Initiative;   University of Cape Town;   Institut Pasteur de Madagascar;   Biomedical Research Center EPLS;   Universidad de Zaragoza;   University of Stellenbosch;   University of KwaZulu;   Wits Health Consortium (Pty) Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Condition:   Tuberculosis Interventions:   Biological: GamTBvac;   Biological: Placebo Sponsor:   Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Condition:   Tuberculosis Interventions:   Biological: MTBVAC;   Biological: BCG Sponsors:   Biofabri, S.L;   TuBerculosis Vaccine Initiative;   University of Cape Town;   Institut Pasteur de Madagascar;   Biomedical Research Center EPLS;   Universidad de Zaragoza;   University of Stellenbosch;   University of KwaZulu;   Wits Health Consortium (Pty) Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Condition:   Tuberculosis Interventions:   Biological: GamTBvac;   Biological: Placebo Sponsor:   Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Condition:   Tuberculosis Interventions:   Biological: MTBVAC;   Biological: BCG Sponsors:   Biofabri, S.L;   TuBerculosis Vaccine Initiative;   University of Cape Town;   Institut Pasteur de Madagascar;   Biomedical Research Center EPLS;   Universidad de Zaragoza;   University of Stellenbosch;   University of KwaZulu;   Wits Health Consortium (Pty) Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Condition:   Tuberculosis Interventions:   Biological: GamTBvac;   Biological: Placebo Sponsor:   Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Condition:   Tuberculosis Interventions:   Biological: MTBVAC;   Biological: BCG Sponsors:   Biofabri, S.L;   TuBerculosis Vaccine Initiative;   University of Cape Town;   Institut Pasteur de Madagascar;   Biomedical Research Center EPLS;   Universidad de Zaragoza;   University of Stellenbosch;   University of KwaZulu;   Wits Health Consortium (Pty) Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Condition:   Tuberculosis Interventions:   Biological: GamTBvac;   Biological: Placebo Sponsor:   Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Condition:   Tuberculosis Interventions:   Biological: MTBVAC;   Biological: BCG Sponsors:   Biofabri, S.L;   TuBerculosis Vaccine Initiative;   University of Cape Town;   Institut Pasteur de Madagascar;   Biomedical Research Center EPLS;   Universidad de Zaragoza;   University of Stellenbosch;   University of KwaZulu;   Wits Health Consortium (Pty) Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Condition:   Tuberculosis Interventions:   Biological: GamTBvac;   Biological: Placebo Sponsor:   Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Condition:   Tuberculosis Interventions:   Biological: MTBVAC;   Biological: BCG Sponsors:   Biofabri, S.L;   TuBerculosis Vaccine Initiative;   University of Cape Town;   Institut Pasteur de Madagascar;   Biomedical Research Center EPLS;   Universidad de Zaragoza;   University of Stellenbosch;   University of KwaZulu;   Wits Health Consortium (Pty) Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials